7 results
P.021 Evaluation of PREEMPT fixed-dose, fixed-site and follow the pain treatment paradigms in the PREDICT Study
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 49 / Issue s1 / June 2022
- Published online by Cambridge University Press:
- 24 June 2022, p. S13
-
- Article
-
- You have access
- Export citation
P.030 Long-term Safety and Tolerability of Atogepant 60 mg Following Once-Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 48 / Issue s3 / November 2021
- Published online by Cambridge University Press:
- 05 January 2022, pp. S28-S29
-
- Article
-
- You have access
- Export citation
P.029 Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 48 / Issue s3 / November 2021
- Published online by Cambridge University Press:
- 05 January 2022, p. S28
-
- Article
-
- You have access
- Export citation
P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, p. S16
-
- Article
-
- You have access
- Export citation
P.014 OnabotulinumtoxinA-treated cervical dystonia patients report improvements in health-related quality of life in a prospective, observational study: POSTURe
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, p. S17
-
- Article
-
- You have access
- Export citation
P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, p. S16
-
- Article
-
- You have access
- Export citation
A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, pp. S9-S10
-
- Article
-
- You have access
- Export citation